Migraine Drugs Market with Top Competitors, Latest Trend, Share, Size, Application, Growth and Forecast to 2025

Global Migraine Drugs Market Research helps companies to obtain market information from different sources, and in multiple formats. It aims to study supply and demand, analyze data as per geography, age factors, demography, technology, product, psychographic & gender differences, and many other parameters. Access to in-depth market trends helps companies to assess the market effectiveness. Some of the multiple techniques used for market research include customer analysis, choice modeling, competition and risk analysis, product research, advertising the research, marketing mix modeling, simulated test marketing, and more.

Global Migraine Drugs Market is expected to reach USD 3.71 billion by 2025, from USD 2.82 billion in 2017 growing at a CAGR of 3.5% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years2015 and 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Get Free Report Sample@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-migraine-drugs-market

Market Definition:

Migraines are severe, incapacitating headaches with an intense throbbing or pulsing in one side of human head. Migraine symptoms include sensitivity to light, sound, smell, creating visual disturbances such as auras, and nausea or vomiting. They are more severe than a normal headache and can affect everyday life of an individual. Migraines are commonly treated with medication. The medication is categorized by two classes of drugs for the treatment of migraine, which involves drugs for acute treatment and preventive treatment, for the reduction in the frequency and severity of headaches. Medicines to stop a migraine are called as abortive medicines prescribed by the doctors. Abortive medicines are taken at the first sign of a migraine, and stops headache before it starts. Medicines to prevent migraines are commonly known as preventive medicines, and are prescribed by the doctors to be taken every day or on the suggestion of the doctor.
According to the study by New England Journal of Medicine (Massachusetts Medical Society), the effectiveness of the drug ‘erenumab’, co-developed by Novartis and Amgen, tested in a trial of 955 people with migraines, and 1,130 people tested for the efficiency of ‘Teva Pharmaceutical’s fremanezumab’. Both drugs have been submitted for approval by the Food and Drug Administration, and their manufacturers are hoping to introduce them to the market in 2018.

Inquiry Before Buying@ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-migraine-drugs-market

The new migraine-specific drugs are being developed by four pharmaceutical companies and they may receive regulatory approval by 2019. These new drugs are not a pill, but injections of laboratory-made molecules known as monoclonal antibodies. The four pharmaceutical companies involved in the development the drugs are Alder BioPharmaceuticals, Amgen, Eli Lilly, and Teva. They all are testing different antibodies, administered at different times. Allergan is also developing a CGRP-neutralizing pill, .Most companies have completed their phase 2 clinical trials and are conducting phase 3 trials; the last rounds of testing are required for FDA approval. So far the results are promising. For instance, the patients in one of Amgen’s trials had to have up to 14 migraines a month to be admitted to the study. After a year of injections, the number migraine is reduced to half each month.

Major Market Drivers and Restraints:

Growing awareness about migraine and its treatment options
Tentative approval of pipeline candidates
High unmet needs
Increased prevalence of migraines
Lack of proper diagnosis
Adverse effects of drugs

For Any query talk to Analyst@ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-migraine-drugs-market

Market Segmentation:

The global migraine drugs market is segmented based on available treatments and route of administration.

Based on available treatments, the global migraine drugs market is segmented into abortive treatment and prophylactic treatment. The abortive treatments market segment is further sub segmented into triptans and ergot alkoids. The prophylactic treatment segment is further sub segmented into botulinum toxin, and topiramate.

On the basis of route of administration, the global migraine drugs market is classified into injectable, oral and others migraine drugs. The other migraine drugs segment is further sub segmented into nasal sprays and transdermal patches.

Based on geography, the global migraine drugs market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Competitive Analysis:

The global migraine drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of migraine drugs market for global, Europe, North America, Asia Pacific and South America.

Major Market Competitors/Players:

Some of the major players operating in the global migraine drugs market are Abbott, Aegis Theraputics, LLC, Aerial BioPharma LLC. , Alder BioPharmaceuticals Inc., Amgen Inc., Astellas Pharma India Private Limited, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Johnson & Johnson Services, Inc, Eisai Co., Ltd., Eli Lilly and Company, Bayer AGSitemap., CoLucid, KOWA Pharmaceuticals America, Inc., Luitpold Pharmaceuticals, Inc., Klaria, Ethypharm, INTELGENX CORP., Global Information, Inc., LePro PharmaCompass OPC Private Limited, Zogenix, Inc., WINSTON PHARMACEUTICALS, Inc., Valeant, TG Therapeutics, Inc., Teva Pharmaceutical Industries Ltd, Horizon Pharma plc., Aralez Pharmaceuticals Inc., RedHill, Pfizer Inc, OptiNose US, Inc, Merck & Co. and Suda Ltd., among others.

Access Full Report@ http://databridgemarketresearch.com/reports/global-migraine-drugs-market/

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research
Tel: +1-888-387-281
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.